Reflux patterns in patients with short-segment Barrett's oesophagus: A study using impedance-pH monitoring off and on proton pump inhibitor therapy

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 5, 2009, Pages 508-515

  Frazzoni, M ^a   Savarino, E ^b   Manno, M ^a   Melotti, G ^a   Mirante, V G ^a   Mussetto, A ^a   Bertani, H ^a   Manta, R ^a   Conigliaro, R ^a  

^a Nuovo Ospedale S Agostino   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; IMPEDANCE; INTESTINE METAPLASIA; MALE; PH MEASUREMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFLUX ESOPHAGITIS;

ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; ESOPHAGEAL PH MONITORING; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MANOMETRY; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 68249114066     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04063.x     Document Type: Article

References (43)

1. Wang KK, Sampliner RE. Updated Guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008 103 : 788 97.
2. Sharma P, Dent J, Armstrong D, et al. The Development and Validation of an Endoscopic Grading System for Barrett's Esophagus: The Prague C & M Criteria. Gastroenterology 2006 131 : 1392 9.
3. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus - The need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998 93 : 1033 6.
4. Boyer J, Laugier R, Chemali M, et al. French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett's oesophagus Endoscopy. Endoscopy 2007 39 : 840 2.
5. Iftikhar SY, James PD, Steele RJ, et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992 33 : 1155 8.
6. Clark GWB, Ireland AP, Peters JH, et al. Short-segment Barrett's esophagus: a prevalent complication of gastroesophageal reflux disease with malignant potential. J Gastrointest Surg 1997 1 : 113 22.
7. Wolfsen HC, Hemminger LL, Wallace MB, et al. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther 2004 20 : 1125 31.
8. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005 129 : 1825 31.
9. Ward EM, Wolfsen HC, Achem SR, et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006 101 : 12 7.
10. Zagari RM, Fuccio L, Wallander M-A, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008 57 : 1354 9.
11. Fass R, Hell RW, Garewal HS, et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001 48 : 310 3.
12. Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002 47 : 256 64.
13. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002 123 : 461 7.
14. Avidan B, Sonnenberg A, Schnell TG, et al. There are no reliable symptoms for erosive oesophagitis and Barrett's oesophagus: endoscopic diagnosis is still essential. Aliment Pharmacol Ther 2002 16 : 735 42.
15. Zentilin P, Conio M, Mele MR, et al. Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. Aliment Pharmacol Ther 2002 16 : 893 8.
16. Frazzoni M, Manno M, De Micheli E, et al. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease: Spectrum disease or distinct phenotypic presentations? Dig Liver Dis, 2006 38 : 643 8.
17. Jankowski J, Sharma P. Review article: approaches to Barrett's oesophagus treatment - the role of proton pump inhibitors and other interventions. Aliment Pharmacol Ther 2004 19 (Suppl. 1 54 9.
18. Hirano I, Richter JE, the Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007 102 : 668 85.
19. Zerbib F, Bruley Des Varannes S, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 2005 22 : 1011 21.
20. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006 101 : 1956 63.
21. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999 45 : 172 80.
22. Frazzoni M, Lonardo A, Grisendi A, et al. Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? A diagnostic and therapeutic study. J Clin Gastroenterol 1993 17 : 101 8.
23. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006 101 : 1900 20.
24. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004 53 : 1024 31.
25. Bredenoord AJ, Hemmink GJM, Smout AJPM. Relationship between gastro-oesophageal reflux pattern and severity of mucosal damage. Neurogastroenterol Motil 2009 21 : 807 12.
26. Kahrilas PJ, Quigley EMM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996 110 : 1982 96.
27. Hila A, Agrawal A, Castell DO. Combined multichannel intraluminal impedance and pH esophageal testing compared to pH alone for diagnosing both acid and weakly acidic gastroesophageal reflux. Clin Gastroenterol Hepatol 2007 5 : 172 7.
28. Roman S, Bruley Des Varannes S, Pouderoux P, et al. Ambulatory 24-h oesophageal impedance-pH recordings: reliability of automatic analysis for gastro-oesophageal reflux assessment. Neurogastroenterol Motil 2006 18 : 978 86.
29. Souza RF, Shewmake K, Terada LS, et al. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002 122 : 299 307.
30. Frazzoni M, De Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003 18 : 1091 8.
31. Bredenoord AJ, Weusten BLAM, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut 2006 55 : 313 8.
32. Leedham S, Jankowski J. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus - the good, the bad, and the flawed Am J Gastroenterol 2007 102 : 21 3.
33. Fass R, Sontag SJ, Traxler B, et al. Treatment of patients with persistent heartburn symptoms: a double blind, randomized trial. Clin Gastroenterol Hepatol 2006 4 : 50 6.
34. Johnson DA, Stacy T, Ryan M, et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005 22 : 129 34.
35. Pehlivanov ND, Olyaee M, Sarosiek I, et al. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 2003 18 : 1 8.
36. Roman S, Serraj I, Damon H, et al. Correlation between gastric pH and gastro-oesophageal reflux contents: ambulatory pH-impedance monitoring results. Neurogastroenterol Motil 2007 19 : 562 8.
37. Hemmink GJM, Bredenoord AJ, Weusten BLAM, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: "on" or "off" proton pump inhibitor? Am J Gastroenterol 2008 103 : 2446 53.
38. Roberts NB. Review article: human pepsins -their multiplicity, function and role in reflux disease. Aliment Pharmacol Ther 2006 24 (Suppl. 2 2 9.
39. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996 111 : 1192 9.
40. Farré R, van Malenstein H, De Vos R, et al. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut 2008 57 : 1366 74.
41. Horwhat JD, Baroni D, Maydonovitch C, et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol 2007 102 : 497 506.
42. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH-monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004 99 : 1037 43.
43. Zentilin P, Iiritano E, Dulbecco P, et al. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Dig Liver Dis 2006 38 : 226 32.